Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens
- Author
- Pieternella Lugtenburg, Antonio Salar Silvestre, Francesca G Rossi, Lucien Noens (UGent) , Wanda Krall, Kate Bendall, Zsolt Szabo and Ulrich Jaeger
- Organization
- Abstract
- Improving the management of elderly patients with lymphoma is of increasing relevance. One thousand one hundred thirteen patients with diffuse large B-cell lymphoma (DLBCL) received rituximab (R)-CHOP (cyclophosphamide, doxorubicin [hydroxydaunorubicin], vincristine [Oncovin], and prednisone) in an observational study. Both older and younger patients failed to receive growth factor support in accordance with international guidelines; patients 65 years and older were more susceptible to febrile neutropenia (FN) and its consequences. Better application of guidelines could reduce rates of FN and improve outcomes.
- Keywords
- Dose-dense, Chemotherapy, Filgrastim, Guidelines, Pegfilgrastim, NON-HODGKINS-LYMPHOMA, CLINICAL-PRACTICE, INTERMEDIATE-GRADE, CHEMOTHERAPY, PEGFILGRASTIM, CYCLOPHOSPHAMIDE, PROPHYLAXIS, VINCRISTINE, DOXORUBICIN, RITUXIMAB
Downloads
-
(...).pdf
- full text
- |
- UGent only
- |
- |
- 520.27 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-3079569
- MLA
- Lugtenburg, Pieternella, et al. “Impact of Age Group on Febrile Neutropenia Risk Assessment and Management in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Regimens.” CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 12, no. 5, 2012, pp. 297–305, doi:10.1016/j.clml.2012.06.004.
- APA
- Lugtenburg, P., Salar Silvestre, A., Rossi, F. G., Noens, L., Krall, W., Bendall, K., … Jaeger, U. (2012). Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 12(5), 297–305. https://doi.org/10.1016/j.clml.2012.06.004
- Chicago author-date
- Lugtenburg, Pieternella, Antonio Salar Silvestre, Francesca G Rossi, Lucien Noens, Wanda Krall, Kate Bendall, Zsolt Szabo, and Ulrich Jaeger. 2012. “Impact of Age Group on Febrile Neutropenia Risk Assessment and Management in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Regimens.” CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 12 (5): 297–305. https://doi.org/10.1016/j.clml.2012.06.004.
- Chicago author-date (all authors)
- Lugtenburg, Pieternella, Antonio Salar Silvestre, Francesca G Rossi, Lucien Noens, Wanda Krall, Kate Bendall, Zsolt Szabo, and Ulrich Jaeger. 2012. “Impact of Age Group on Febrile Neutropenia Risk Assessment and Management in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Regimens.” CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 12 (5): 297–305. doi:10.1016/j.clml.2012.06.004.
- Vancouver
- 1.Lugtenburg P, Salar Silvestre A, Rossi FG, Noens L, Krall W, Bendall K, et al. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2012;12(5):297–305.
- IEEE
- [1]P. Lugtenburg et al., “Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens,” CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 12, no. 5, pp. 297–305, 2012.
@article{3079569,
abstract = {{Improving the management of elderly patients with lymphoma is of increasing relevance. One thousand one hundred thirteen patients with diffuse large B-cell lymphoma (DLBCL) received rituximab (R)-CHOP (cyclophosphamide, doxorubicin [hydroxydaunorubicin], vincristine [Oncovin], and prednisone) in an observational study. Both older and younger patients failed to receive growth factor support in accordance with international guidelines; patients 65 years and older were more susceptible to febrile neutropenia (FN) and its consequences. Better application of guidelines could reduce rates of FN and improve outcomes.}},
author = {{Lugtenburg, Pieternella and Salar Silvestre, Antonio and Rossi, Francesca G and Noens, Lucien and Krall, Wanda and Bendall, Kate and Szabo, Zsolt and Jaeger, Ulrich}},
issn = {{2152-2650}},
journal = {{CLINICAL LYMPHOMA MYELOMA & LEUKEMIA}},
keywords = {{Dose-dense,Chemotherapy,Filgrastim,Guidelines,Pegfilgrastim,NON-HODGKINS-LYMPHOMA,CLINICAL-PRACTICE,INTERMEDIATE-GRADE,CHEMOTHERAPY,PEGFILGRASTIM,CYCLOPHOSPHAMIDE,PROPHYLAXIS,VINCRISTINE,DOXORUBICIN,RITUXIMAB}},
language = {{eng}},
number = {{5}},
pages = {{297--305}},
title = {{Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens}},
url = {{http://doi.org/10.1016/j.clml.2012.06.004}},
volume = {{12}},
year = {{2012}},
}
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: